SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders.
J Hematol Oncol
; 15(1): 54, 2022 05 07.
Article
Dans Anglais
| MEDLINE | ID: covidwho-1951282
ABSTRACT
BACKGROUND:
The clinical efficacy of SARS-CoV-2 vaccines according to antibody response in immunosuppressed patients such as hematological patients has not yet been established. PATIENTS ANDMETHODS:
A prospective multicenter registry-based cohort study conducted from December 2020 to December 2021 by the Spanish transplant and cell therapy group was used to analyze the relationship of antibody response at 3-6 weeks after full vaccination (2 doses) with breakthrough SARS-CoV-2 infection in 1394 patients with hematological disorders.RESULTS:
At a median follow-up of 165 days after complete immunization, 37 out of 1394 (2.6%) developed breakthrough SARS-CoV-2 infection at median of 77 days (range 7-195) after full vaccination. The incidence rate was 6.39 per 100 persons-year. Most patients were asymptomatic (19/37, 51.4%), whereas only 19% developed pneumonia. The mortality rate was 8%. Lack of detectable antibodies at 3-6 weeks after full vaccination was the only variable associated with breakthrough infection in multivariate logistic regression analysis (Odds Ratio 2.35, 95% confidence interval 1.2-4.6, p = 0.012). Median antibody titers were lower in cases than in non-cases [1.83 binding antibody units (BAU)/mL (range 0-4854.93) vs 730.81 BAU/mL (range 0-56,800), respectively (p = 0.007)]. We identified 250 BAU/mL as a cutoff above which incidence and severity of the infection were significantly lower.CONCLUSIONS:
Our study highlights the benefit of developing an antibody response in these highly immunosuppressed patients. Level of antibody titers at 3 to 6 weeks after 2-dose vaccination links with protection against both breakthrough infection and severe disease for non-Omicron SARS-CoV-2 variants.Mots clés
Texte intégral:
Disponible
Collection:
Bases de données internationales
Base de données:
MEDLINE
Sujet Principal:
COVID-19
/
Hémopathies
Type d'étude:
Étude de cohorte
/
Étude observationnelle
/
Étude pronostique
Les sujets:
Covid long
/
Vaccins
/
Variantes
Limites du sujet:
Humains
langue:
Anglais
Revue:
J Hematol Oncol
Thème du journal:
Hématologie
/
Tumeurs
Année:
2022
Type de document:
Article
Pays d'affiliation:
S13045-022-01275-7
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS